Evaluation of an ultra-low-dose oral contraceptive for dysmenorrhea: a placebo-controlled, double-blind, randomized trial

Tasuku Harada, Mikio Momoeda
Fertility and sterility · 2016 · vol. 106(7) , pp. 1807–1814 · doi:10.1016/j.fertnstert.2016.08.051 · PMID:27717552 · W2528775644
RCT OA: closed CC0 ⤵ 6 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-18 ⓘ

This trial found that the ultra-low-dose contraceptive NPC-01 reduced dysmenorrhea scores significantly more than placebo and was comparable in efficacy to IKH-01, though with a higher incidence of previously reported side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To evaluate the efficacy and safety of an ultra-low-dose oral contraceptive (NPC-01; 0.02 mg ethinyl estradiol and 1 mg norethisterone) in subjects with dysmenorrhea. DESIGN: Placebo-controlled, double-blind, randomized trial. SETTING: Clinical trial sites. PATIENT(S): Two hundred fifteen subjects with dysmenorrhea. INTERVENTION(S): Subjects were randomly assigned to receive NPC-01, placebo, or IKH-01 (0.035 mg ethinyl estradiol and 1 mg norethisterone) for four cycles. MAIN OUTCOME MEASURE(S): Total dysmenorrhea score (verbal rating scale) assessing pain on the basis of limited ability to work and need for analgesics. RESULT(S): The reductions of total dysmenorrhea score and visual analog scale score after the treatment were significantly higher in the NPC-01 group than in the placebo group. Furthermore, the efficacy of NPC-01 was comparable to that of IKH-01. The overall incidence of side effects was significantly higher in the NPC-01 group than in the placebo group. All side effects that occurred in the NPC-01 group were previously reported in patients receiving IKH-01. No serious side effects occurred. CONCLUSION(S): The ultra-low-dose contraceptive NPC-01 relieved dysmenorrhea as effectively as IKH-01. Thus, NPC-01 could represent a new option for long-term treatment of dysmenorrhea. CLINICAL TRIAL IDENTIFICATION NUMBER: NCT01129102.

My notes (saved in your browser only)

Condition tags

dysmenorrhea

MeSH descriptors

Contraceptives, Oral, Combined Contraceptives, Oral, Hormonal Dysmenorrhea Ethinyl Estradiol Menstrual Cycle Norethindrone Administration, Oral Adult Analgesics Analgesics Contraceptives, Oral, Combined Contraceptives, Oral, Combined Contraceptives, Oral, Hormonal Contraceptives, Oral, Hormonal Double-Blind Method Dysmenorrhea Dysmenorrhea Dysmenorrhea Ethinyl Estradiol Ethinyl Estradiol

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (23)

Cited by (6)

Source provenance

openalex
last seen: 2026-05-11T05:42:58.953575+00:00
pubmed
last seen: 2026-10-08T21:18:43.609252+00:00
unpaywall
last seen: 2026-09-17T06:32:46.214484+00:00
License: CC0 · commercial use OK